These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
595 related articles for article (PubMed ID: 26362528)
21. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563 [TBL] [Abstract][Full Text] [Related]
22. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. Hofmeister CC; Lonial S J Clin Oncol; 2016 Dec; 34(36):4421-4430. PubMed ID: 27998219 [TBL] [Abstract][Full Text] [Related]
24. Daratumumab: monoclonal antibody therapy to treat multiple myeloma. Xia C; Ribeiro M; Scott S; Lonial S Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963 [TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Wudhikarn K; Wills B; Lesokhin AM Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009 [TBL] [Abstract][Full Text] [Related]
26. Multiple Myeloma Gets Three New Drugs. Poh A Cancer Discov; 2016 Jan; 6(1):4. PubMed ID: 26658418 [TBL] [Abstract][Full Text] [Related]
28. Daratumumab for the Treatment of Multiple Myeloma. Plesner T; Krejcik J Front Immunol; 2018; 9():1228. PubMed ID: 29915586 [TBL] [Abstract][Full Text] [Related]
29. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma. Grosicki S; Barchnicka A Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214 [TBL] [Abstract][Full Text] [Related]
30. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Palumbo A; Sonneveld P Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331 [TBL] [Abstract][Full Text] [Related]
31. The role of SLAMF7 in multiple myeloma: impact on therapy. Boudreault JS; Touzeau C; Moreau P Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202 [TBL] [Abstract][Full Text] [Related]
32. Safety issues and management of toxicities associated with new treatments for multiple myeloma. Brioli A; Mügge LO; Hochhaus A; Von Lilienfeld-Toal M Expert Rev Hematol; 2017 Mar; 10(3):193-205. PubMed ID: 28116920 [TBL] [Abstract][Full Text] [Related]
33. Advances and practical use of monoclonal antibodies in multiple myeloma therapy. Lee HC; Weber DM Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523 [TBL] [Abstract][Full Text] [Related]
34. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Kuroda J; Nagoshi H; Shimura Y; Taniwaki M Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207 [TBL] [Abstract][Full Text] [Related]
35. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740 [TBL] [Abstract][Full Text] [Related]
36. Practical Considerations for Antibodies in Myeloma. Laubach JP; van de Donk N; Davies FE; Mikhael J Am Soc Clin Oncol Educ Book; 2018 May; 38():667-674. PubMed ID: 30231321 [TBL] [Abstract][Full Text] [Related]
37. The Anti-CD38 Antibody Therapy in Multiple Myeloma. Petrucci MT; Vozella F Cells; 2019 Dec; 8(12):. PubMed ID: 31842517 [TBL] [Abstract][Full Text] [Related]